section name header

Evidence summaries

Prazosin for Raynaud's Phenomenon in Progressive Systemic Sclerosis

Prazosin may be modestly effective in the treatment of Raynaud's phenomenon secondary to scleroderma. Level of evidence: "C"

Two trials with a total of 40 patients were included in a Cochrane review [Abstract] 1. Prazosin has been found in two randomised cross-over trials to be more effective than placebo. However, the positive response is modest and side effects are not rare.

Comment: The quality of evidence is downgraded by imprecise results (limited study size for each comparison) and by potential reporting bias.

    References

    • Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 1998;(2):CD000956.

Primary/Secondary Keywords